Picard Medical’s Artificial Heart Bridges 21-Year-Old Patient for 2.5 Months to Transplant
Picard Medical’s SynCardia Total Artificial Heart sustained a 21-year-old patient through 2.5 months of circulatory support at Texas Children’s Hospital following rejection of his initial transplant, enabling successful re-transplantation. The company is also advancing its Emperor fully implantable artificial heart, targeting future transplantation alternatives and broader market adoption.
1. Successful STAH Bridge to Transplant
At Texas Children’s Hospital, surgeons implanted the SynCardia Total Artificial Heart in a 21-year-old patient after rejection of his 2017 transplant, providing 2.5 months of full circulatory support before a donor heart became available. The support period stabilized organ function and enabled a successful re-transplantation.
2. Device Design and Clinical Advantages
The SynCardia Total Artificial Heart replaces both ventricles in end-stage biventricular failure patients, offering external pneumatic driver support to maintain circulation. With more than 2,100 implants performed across 27 countries, it remains the only commercially approved artificial heart in the United States and Canada.
3. Next-Generation Emperor Artificial Heart Development
Picard Medical is advancing the Emperor Total Artificial Heart, a fully implantable system designed to eliminate external drivers and expand long-term mechanical support. The next-generation device aims to serve as an alternative to transplantation for select advanced heart failure patients.